T. BABACAN Et Al. , "Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer," TUMORI J , vol.101, no.4, pp.418-423, 2015
BABACAN, T. Et Al. 2015. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer. TUMORI J , vol.101, no.4 , 418-423.
BABACAN, T., Efe, O., Hasirci, A. S., Demirci, F., Buyukhatipoglu, H., Balakan, O., ... Sarici, F.(2015). Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer. TUMORI J , vol.101, no.4, 418-423.
BABACAN, TANER Et Al. "Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer," TUMORI J , vol.101, no.4, 418-423, 2015
BABACAN, TANER Et Al. "Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer." TUMORI J , vol.101, no.4, pp.418-423, 2015
BABACAN, T. Et Al. (2015) . "Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer." TUMORI J , vol.101, no.4, pp.418-423.
@article{article, author={TANER BABACAN Et Al. }, title={Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer}, journal={TUMORI J}, year=2015, pages={418-423} }